Ocrelizumab (Okrelizumab)
| Use attributes for filter ! | |
| Target | CD20 |
|---|---|
| Formula | C6494H9978N1718O2014S46 |
| Source | Humanized (from mouse) |
| ATC code | L04AA36 (WHO) |
| Music groups | Natalizumab |
| Alemtuzumab | |
| Cladribine | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951381 |
About Ocrelizumab (Okrelizumab)
Ocrelizumab, sold under the brand name Ocrevus, is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.